Literature DB >> 32652312

Recent advances in multitarget-directed ligands targeting G-protein-coupled receptors.

Hongguang Ma1, Boshi Huang1, Yan Zhang2.   

Abstract

Mounting evidence indicates that single-target drugs might be inadequate to achieve satisfactory therapeutic effects on complex diseases. Recently, increasing attention has been paid to developing drugs that can manipulate multiple targets to generate beneficial effects through potential synergy. G-protein-coupled receptors (GPCRs) become desirable targets for developing multitarget-directed ligands (MTDLs) because of their crucial roles in the pathophysiology of various human diseases and the accessibility of druggable sites at the cell surface. Herein, we review the most recent advances in the development of GPCR-targeted MTDLs in treating complex diseases, and discuss their potential therapeutic strategies to reveal current trends and shed insights into the utility of GPCR-targeted MTDLs for future drug design and development.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2020        PMID: 32652312      PMCID: PMC7572774          DOI: 10.1016/j.drudis.2020.07.004

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  80 in total

Review 1.  Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia.

Authors:  Bryan L Roth; Douglas J Sheffler; Wesley K Kroeze
Journal:  Nat Rev Drug Discov       Date:  2004-04       Impact factor: 84.694

Review 2.  Novel paradigms for drug discovery: computational multitarget screening.

Authors:  Ekachai Jenwitheesuk; Jeremy A Horst; Kasey L Rivas; Wesley C Van Voorhis; Ram Samudrala
Journal:  Trends Pharmacol Sci       Date:  2008-01-10       Impact factor: 14.819

Review 3.  Adverse effects of antipsychotic medications.

Authors:  John Muench; Ann M Hamer
Journal:  Am Fam Physician       Date:  2010-03-01       Impact factor: 3.292

Review 4.  Shifting from the single to the multitarget paradigm in drug discovery.

Authors:  José L Medina-Franco; Marc A Giulianotti; Gregory S Welmaker; Richard A Houghten
Journal:  Drug Discov Today       Date:  2013-01-20       Impact factor: 7.851

Review 5.  Current status of GPR40/FFAR1 modulators in medicinal chemistry (2016-2019): a patent review.

Authors:  Zheng Li; Zongtao Zhou; Luyong Zhang
Journal:  Expert Opin Ther Pat       Date:  2019-12-02       Impact factor: 6.674

Review 6.  Multitarget opioid ligands in pain relief: New players in an old game.

Authors:  Rita Turnaturi; Giuseppina Aricò; Giuseppe Ronsisvalle; Carmela Parenti; Lorella Pasquinucci
Journal:  Eur J Med Chem       Date:  2015-11-22       Impact factor: 6.514

7.  Synthesis, pharmacological and structural studies of 5-substituted-3-(1-arylmethyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as multi-target ligands of aminergic GPCRs.

Authors:  Magda Kondej; Tomasz M Wróbel; Andrea G Silva; Piotr Stępnicki; Oliwia Koszła; Ewa Kędzierska; Agata Bartyzel; Grażyna Biała; Dariusz Matosiuk; Maria I Loza; Marián Castro; Agnieszka A Kaczor
Journal:  Eur J Med Chem       Date:  2019-07-20       Impact factor: 6.514

8.  Discovery of aryl-piperidine derivatives as potential antipsychotic agents using molecular hybridization strategy.

Authors:  Chen Zhu; Xinwei Li; Bangyi Zhao; Weiqing Peng; Wei Li; Wei Fu
Journal:  Eur J Med Chem       Date:  2020-03-10       Impact factor: 6.514

9.  Synthesis and biological evaluation of new multi-target 3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives with potential antidepressant effect.

Authors:  Martyna Z Wróbel; Andrzej Chodkowski; Franciszek Herold; Monika Marciniak; Maciej Dawidowski; Agata Siwek; Gabriela Starowicz; Katarzyna Stachowicz; Bernadeta Szewczyk; Gabriel Nowak; Mariusz Belka; Tomasz Bączek; Grzegorz Satała; Andrzej J Bojarski; Jadwiga Turło
Journal:  Eur J Med Chem       Date:  2019-09-26       Impact factor: 6.514

10.  Synthesis of new 4-butyl-arylpiperazine-3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives and evaluation for their 5-HT1A and D2 receptor affinity and serotonin transporter inhibition.

Authors:  Martyna Z Wróbel; Andrzej Chodkowski; Monika Marciniak; Maciej Dawidowski; Anna Maksymiuk; Agata Siwek; Gabriel Nowak; Jadwiga Turło
Journal:  Bioorg Chem       Date:  2020-02-12       Impact factor: 5.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.